Clinical Trial

Dendritic Cell Vaccine to Prevent COVID-19

Name: Dendritic Cell Vaccine to Prevent COVID-19 — clinical trial record (NCT07501208)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Unknown Phase 1

View on ClinicalTrials.gov →

Summary

This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.

Protocol Amendment History 1 change

notable Primary completion pushed: 2020-12-07 -> 2021-01-31 2026-04-12

Trial Details

NCT Number	NCT07501208
Lead Sponsor	Ina-Respond Collaborators: Aivita Biomedical, Inc., PT AIVITA Biomedika Indonesia, National Institute of Health Research and Development, Ministry of Health Republic of Indonesia, RSUP Dr. Kariadi Semarang, indonesia, Faculty of Medicine University of Diponegoro, Indonesia
Conditions	COVID-19
Enrollment	27 participants
Start Date	2020-12-07
Primary Completion	2021-01-31 (estimated)
Study Completion	2022-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-30